Regulus Therapeutics’ (RGLS) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Regulus Therapeutics (NASDAQ:RGLS) in a report released on Wednesday,Benzinga reports. The brokerage currently has a $10.00 price target on the biopharmaceutical company’s stock.

Regulus Therapeutics Trading Up 7.1 %

NASDAQ RGLS opened at $1.36 on Wednesday. The firm has a market capitalization of $89.08 million, a P/E ratio of -1.27 and a beta of 1.58. The firm’s fifty day moving average price is $1.33 and its two-hundred day moving average price is $1.49. Regulus Therapeutics has a 1 year low of $0.83 and a 1 year high of $3.79.

Insider Activity

In other Regulus Therapeutics news, insider Preston Klassen sold 31,445 shares of Regulus Therapeutics stock in a transaction on Monday, January 13th. The shares were sold at an average price of $1.26, for a total transaction of $39,620.70. Following the completion of the transaction, the insider now directly owns 36,055 shares of the company’s stock, valued at $45,429.30. The trade was a 46.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Christopher Ray Aker sold 38,547 shares of the stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $1.26, for a total transaction of $48,569.22. Following the completion of the transaction, the vice president now directly owns 54,634 shares in the company, valued at $68,838.84. The trade was a 41.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 223,998 shares of company stock valued at $282,237. 4.35% of the stock is owned by company insiders.

Institutional Trading of Regulus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. NEA Management Company LLC bought a new position in Regulus Therapeutics in the 3rd quarter valued at about $10,154,000. Octagon Capital Advisors LP grew its position in shares of Regulus Therapeutics by 13.7% in the fourth quarter. Octagon Capital Advisors LP now owns 4,848,802 shares of the biopharmaceutical company’s stock valued at $7,661,000 after purchasing an additional 585,101 shares during the last quarter. Millennium Management LLC increased its stake in shares of Regulus Therapeutics by 69.7% during the fourth quarter. Millennium Management LLC now owns 2,192,158 shares of the biopharmaceutical company’s stock worth $3,464,000 after purchasing an additional 900,743 shares during the period. State Street Corp lifted its holdings in Regulus Therapeutics by 3.5% during the 3rd quarter. State Street Corp now owns 1,000,998 shares of the biopharmaceutical company’s stock worth $1,572,000 after purchasing an additional 33,496 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in Regulus Therapeutics in the 3rd quarter valued at $1,403,000. Institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.